ublituximab placebo

DRUG2 trials

Sponsors

Tg Therapeutics Inc.

Conditions

Relapsing Multiple SclerosisRelapsing multiple sclerosis

Phase 2

Ublituximab in Pediatric Participants with Relapsing forms of Multiple Sclerosis (RMS)

Not yet recruitingCTIS2025-522257-19-00

Tg Therapeutics Inc.Relapsing Multiple Sclerosis

Target: 40Updated: 2025-12-22

Phase 3

Evaluating safety, efficacy and pharmacokinetics of a modified regimen of ublituximab (ENHANCE)

Active, not recruitingCTIS2024-519284-18-00

Tg Therapeutics Inc.Relapsing multiple sclerosis

Start: 2025-06-18Target: 233Updated: 2025-12-14